论文部分内容阅读
As a new class of drugs to prevent venous thromboembolism, Factor Xa inhibitor showed wider safety window than warfarin.CPRC2, a new oral specific Factor Xa inhibitor, is currently under clinical development.A Phase Ⅰ clinical trial including single dose study and multiple dose study has been conducted in 24 healthy Chinese subjects aged from 21-44 years old in our Unit.Blood and urine were sampled according to scheduled time.